Osteoporosis Clinical Trials in Philadelphia

Showing 1-20 of 52 trials

The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures

NCT07027306

This is an international multicenter prospective observational study. Patients with radiologically confirmed, symptomatic, single- or multilevel contiguous TL (from T1 to L5) fractures as a result of primary osteoporosis will be recruited from participating clinics/hospitals (ie, study sites). Fractures included are insufficiency fractures (confirmed by magnetic resonance imaging \[MRI\]) and traumatic fractures (low-energy trauma, confirmed by computed tomography \[CT\] or MRI).

Osteoporotic FracturesOsteoporosis

AO Foundation, AO Spine648 participantsStarted Mar 2026

San Francisco, California, United States • Philadelphia, Pennsylvania, United States • Buenos Aires, Argentina +12 more locations

COMPLETEDPhase 3< 1 mile

Open Label Extension Study of PREOS

NCT00172133

This is an Open Label Extension Study (OLES) for patients who participated in the 18 month double-blind, placebo-controlled, Phase III trial (Protocol ALX1 11 93001 the TOP Study) studying the effect of ALX1-11, recombinant human parathyroid hormone, rhPTH(1-84), on vertebral fracture incidence. The primary objective of this study is to evaluate the safety of continued dosing with ALX1-11, up to a maximum of 24 months, in postmenopausal osteoporotic women who participated in Protocol ALX1 11 93001.

Osteoporosis

Shire1,683 participantsStarted Oct 2001

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Phoenix, Arizona, United States +129 more locations

The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures

Open Label Extension Study of PREOS

Osteoporosis Trials in Other Cities

TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis

Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density

Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis

Vitamin D Supplementation in Obesity and Weight Loss (3DD Study)

A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis

Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3

RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE

OsteoPorotic fracTure preventION System (OPTIONS) Research Study

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)

A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis

Prevention of Injury in Skilled Nursing Facilities Through Optimizing Medications

Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption

An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids

1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids

A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.

Other Conditions in Philadelphia